CAR T-Cell Therapy for Relapsed/Refractory Non-Hodgkin’s Lymphoma: A Comprehensive Review

Abstract: Non-Hodgkin lymphoma (NHL) is the seventh most common type of malignancy worldwide, with approximately 544,000 cases diagnosed in 2020.1-3 The vast majority of NHLs are […]

Chimeric Antigen Receptor Natural Killer Cells for the Treatment of Patients With B-Cell Malignancies

H&O What are the outcomes associated with chimeric antigen receptor (CAR) T-cell therapy in patients with non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL)? KR […]

Improving Outcomes With Checkpoint Blockade in Non-Hodgkin Lymphoma

H&O How effective are standard treatments for non-Hodgkin lymphoma (NHL)? JB There are effective therapies for diffuse large B-cell lymphoma (DLBCL), which is the most […]

Surveillance Scanning in Lymphoma

Abstract: Although the role of imaging in the management of most lymphomas is well established at baseline, during treatment, and following treatment, surveillance imaging after […]

Zanubrutinib: A Novel BTK Inhibitor in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

H&O What type of drug is zanubrutinib? CT Zanubrutinib, also known as BGB-3111, is a next-generation Bruton’s tyrosine kinase (BTK) inhibitor. It inhibits BTK irreversibly […]

Cellular Immunotherapy for Non-Hodgkin Lymphoma

H&O What types of cellular immunotherapy are being investigated in non-Hodgkin lymphoma? CB It is important to distinguish between the types of cellular immunotherapy available […]

An Interim Analysis of the ZUMA-1 Study of KTE-C19 in Refractory, Aggressive Non-Hodgkin Lymphoma

H&O What are the current treatment approaches for patients with refractory aggressive DLBCL? SN The standard frontline therapy for diffuse large B-cell lymphoma (DLBCL) is […]